Unilever has signed a research agreement with a US company in order to explore transdermal delivery technologies. Massachusetts-based BioChemics developed its transdermal drug delivery system VALE Vasi-active Lipid Encapusulated initially for use in the pharmaceutical sector, but it believes it has potential cosmetic applications. The company has signed the agreement with the Anglo-Dutch consumer goods
via #atssh-twitter.
By Katie Bird , 06-Oct-09Â www.cosmeticsdesign-europe.com
